Invetech says its Korus tech will offer an autologous cell therapy system that provides an option with minimal tech transfer challenges.

Dan Stanton, Managing editor

June 22, 2022

1 Min Read
Invetech launches closed autologous cell therapy tech

Invetech says its Korus technology will offer industry an autologous cell therapy system that provides an option with minimal tech transfer challenges.

With the Korus system launched this week, Invetech is targeting autologous cell therapy developers, including those in the CAR-T, TIL, NK, DC therapeutics areas, who are looking to start their cell therapy manufacturing process with cleaner lymphocyte or monocyte populations – and improve their overall manufacturing yield.

The closed system includes elutriation and cell wash using gentle counterflow centrifugation and the firm claims it has supporting data demonstrating improved manufacturing performance compared to samples prepared by standard washing.


“Korus, like other elutriation-based devices, can save overall process cost by reducing the amount of off-target cells in starting material which can reduce expensive inputs like virus and selection agents,” an Invetech spokesperson told BioProcess Insider.

“Its wide processing volume range also allows autologous cell therapy makers to process an entire apheresis in one pass for elutriation, instead of having to use multiple units. It is also capable of performing downstream wash and concentrate processes down to 25ml.”

According to the firm, the Korus system can result in a 31% purer lymphocyte population, 49% improvement in T cell recovery after selection, 70% more T cells during expansion, and a 2.5x improvement in manufacturing yield.

It will also give industry an elutriation option that can handle relevant volume ranges from 25 ml to 5 L, we were told. “With the uncertainty around the availability of legacy elutriation systems in 2023, Korus provides an option with minimal tech transfer challenges.”

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like